cisapride has been researched along with Cardiac Hypertrophy in 1 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cisapride has been shown to have electrophysiological effects on the heart." | 5.40 | Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3. ( Bai, X; Chege Gitau, S; Chu, W; Ju, J; Li, S; Liu, D; Lu, Y; Wu, Y; Xu, C; Yuan, W; Zhang, Q; Zhao, T; Zhou, X, 2014) |
| "Cisapride has been shown to have electrophysiological effects on the heart." | 1.40 | Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3. ( Bai, X; Chege Gitau, S; Chu, W; Ju, J; Li, S; Liu, D; Lu, Y; Wu, Y; Xu, C; Yuan, W; Zhang, Q; Zhao, T; Zhou, X, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, X | 1 |
| Zhang, Q | 1 |
| Zhao, T | 1 |
| Bai, X | 1 |
| Yuan, W | 1 |
| Wu, Y | 1 |
| Liu, D | 1 |
| Li, S | 1 |
| Ju, J | 1 |
| Chege Gitau, S | 1 |
| Chu, W | 1 |
| Xu, C | 1 |
| Lu, Y | 1 |
1 other study available for cisapride and Cardiac Hypertrophy
| Article | Year |
|---|---|
Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Topics: Animals; Calcineurin; Cardiomegaly; Cardiotonic Agents; Cisapride; Male; Myocytes, Cardiac; NFATC Tr | 2014 |